NCT02693535 2026-03-19
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
Clinical Trials
12 trialsNCT05675410 2026-03-19
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT05272384 2026-03-18
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT03681561 2026-03-09
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Big Ten Cancer Research Consortium
Phase 1/2 Recruiting
NCT03258567 2026-03-06
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03297606 2026-03-04
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT06984146 2025-11-26
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
National Medical Research Radiological Centre of the Ministry of Health of Russia
Phase 2 Recruiting
NCT03017820 2025-10-08
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT07209059 2025-10-06
FINISH-HL
National Research Center for Hematology, Russia
Phase 2 Recruiting
NCT06812858 2025-08-19
PD-1 Inhibitors Maintenance for cHL Post-autoHCT
St. Petersburg State Pavlov Medical University
Phase 2 Recruiting
NCT05595447 2025-03-12
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
Hospital Regional de Alta Especialidad del Bajio
Phase 2/3 Recruiting
NCT04866654 2021-08-12
RAFTING
Medical University of Gdansk
Phase 2 Recruiting